Roche’s Neuroscience segment revenue trends
Roche’s (RHHBY) Neurology segment generated net combined revenues of 1.4 billion Swiss francs in the first half of this year, reflecting 164.0% YoY (year-over-year) growth on a constant exchange basis. This segment consists of Ocrevus, Madopar, and other drugs. Ocrevus primarily pushed the revenue growth of Roche’s Neurology business.
Roche’s Ocrevus and Madopar reported revenues of 1.04 billion Swiss francs and 182.0 million Swiss francs, respectively, in the first half of this year, reflecting ~456.0% and ~9.0% growth on a constant exchange basis.
In the first half, Ocrevus, Perjeta, Alecensa, and Tecentriq primarily pushed Roche’s revenue growth. Roche’s net revenues grew from 26.3 billion Swiss francs in the first half of 2017 to 28.1 billion Swiss francs in the first half of this year.
Roche’s Pharmaceuticals division and Diagnostics Division reported revenues of 21.8 billion Swiss francs and 6.3 billion Swiss francs, respectively, reflecting ~7.0% and ~6.0% YoY growth on the constant exchange basis.
In July, the FDA granted a Breakthrough Therapy Designation to Roche’s (RHHBY) Elecsys beta-amyloid cerebrospinal fluid (or CSF) and Elecsys phosphor-Tau CSF. Elecsys beta-amyloid CSF and Elecsys phosphor-Tau CSF are two in vitro diagnostic immunoassays that can measure the beta-amyloid and phosphor tau concentrations, respectively, in the CSF. The immunoassays can be used to determine beta-amyloid and phosphor tau in individuals with cognitive disorders and who are being evaluated for Alzheimer’s disease.
In August, the EMA (European Medicines Agency) granted a PRIME (Priority Medicine) designation to Roche’s RG6042, an investigational therapy for the treatment of individuals with Huntington’s disease. In the clinical studies, RG6042 showed the capability to reduce the mutant huntingtin protein (or mHTT), a toxin that is believed to cause Huntington’s disease.
In October, Roche announced new interim data from the dose-evaluation sections of the FIREFISH and SUNFISH trials. Roche is conducting the FIREFISH and SUNFISH trials to evaluate the safety and efficacy of risdiplam in individuals with spinal muscular dystrophy.
Interim evaluation of the Part 1 FIREFISH trial showed that infants with type 1 spinal muscular dystrophy could achieve the developmental milestones. Also, the interim results of the Part 1 SUNFISH trial demonstrated that individuals with type 2/3 spinal muscular dystrophy showed improvement in their motor functions.